Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm

Jonathan Golledge, Bradford Cullen, Catherine Rush, Corey S. Moran, Emma Secomb, Frances Wood, Alan Daugherty, Julie H. Campbell, Paul E. Norman

Research output: Contribution to journalArticlepeer-review

76 Scopus citations

Abstract

Objective: Osteopontin (OPN) is associated with human abdominal aortic aneurysms (AAA) and in vitro studies suggest that this cytokine is downregulated by peroxisome proliferator-activated receptor (PPAR) ligation. We examined the effect of two PPAR ligands within a mouse model of aortic aneurysm. Methods: At 11 weeks of age apolipoprotein E deficient (ApoE-/-) mice were given pioglitazone (n=27), fenofibrate (n=27) or vehicle (n=27) in their drinking water. From 13 weeks of age mice received angiotensin II (1μg/kg/min) infusion via subcutaneous pumps until death or 17 weeks when the aortas were harvested and maximum aortic diameters were recorded. Suprarenal aortic segments were assessed for OPN concentration and macrophage accumulation. Saline infused mice served as negative controls (n=22). Results: Angiotensin II induced marked dilatation in the suprarenal aorta (>2-fold increase compared to controls) associated with upregulation of the cytokines OPN and macrophage infiltration. Suprarenal aortic expansion was significantly reduced by administration of pioglitazone (mean diameter 1.61 ± 0.11. mm, p=0.011) and fenofibrate (mean diameter 1.51 ± 0.13. mm, p=0.001) compared to the vehicle control group (mean diameter 2.10 ± 0.14. mm). Immunostaining for macrophages was reduced in mice treated with pioglitazone (median staining area 6.2%, interquartile range 4.1-7.2, p<0.001) and fenofibrate (median staining area 4.0%, interquartile range 2.2-6.1, p<0.001) compared to mice receiving vehicle control (median staining area 13.2%, interquartile range 8.4-20.0). Conclusion: These findings suggest the potential value of peroxisome proliferator-activated receptor ligation as a therapy for human AAAs.

Original languageEnglish
Pages (from-to)51-56
Number of pages6
JournalAtherosclerosis
Volume210
Issue number1
DOIs
StatePublished - May 2010

Bibliographical note

Funding Information:
Grants from the National Institute of Health , USA ( RO1 HL080010-01 ) and NHMRC (project grant 379600 ) supported this work. JG and PEN are supported by Practitioner Fellowships from the NHMRC, Australia (431503 and 458505). ES was supported by a 1 year scholarship from The Royal Australasian College of Surgeons.

Keywords

  • Aortic aneurysm
  • Medication
  • Treatment

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm'. Together they form a unique fingerprint.

Cite this